Abstract
Breakthrough Therapy Designation (BTD) is an expedited drug pathway frequently used to bring oncology drugs to market. Historically, oncology drugs have high rates of adverse events (AEs). In this study, we compare post-marketing adverse events (PMAEs) in oncology medications approved with BTD vs. without BTD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
